Blood-based DNA methylation marker model for short-term and long-term lung cancer risk prediction

• by Megha Bhardwaj, Yi-Qian Sun, Clara Frick, Ben Schöttker, Oluf Dimitri Røe, Bernd Holleczek, Xiao-Mei Mai, Hermann Brenner

• June 6, 2026

Lymph Node Dissection and Postoperative Complications After Lung Cancer Resection

• by Isheeta Madeka, Khaled Noueihed, Jacob Woodroof, Shale Mack, Hamza Rshaidat, Gregory L. Whitehorn, Sneha Alaparthi, Scott H. Koeneman, Tyler R. Grenda, Nathaniel R. Evans, Olugbenga T. Okusanya

• June 1, 2026

Ancestry informative genetic variants associated with tobacco metabolic and detoxification capacity measured by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) among smokers

• by Oladimeji Lanade, Zhongxuan He, Yan Zhou, Elizabeth Blackman, Denise Gibbs, Sharon Harrison, Karthik Devarajan, Mark Andrake, Roland L. Dunbrack, Gerald Nkogbu, Aditi Wagh, Michael Slifker, Cherie Erkmen, Freda Patterson, Aditi Satti, Heather-Dawn Lawson-Myers, Robin Roberts, Don Mitchell, Jeffery C. Liu, Joel Erblich, Camille Ragin

• July 14, 2026

ASCO26: Julia Rotow, MD, Silevertinib in Lung Cancer

Dana-Farber Cancer Institute's Dr. Julia Rotow reported on a study looking at silevertinib, with data showing it may offer a new first-line option for hard-to-treat EGFR non-small cell lung cancer variants, with encouraging brain activity and manageable side effects.

• July 1, 2026

• 1 min